How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Colon and Rectal Carcinoma Market
- By Cancer Stage: Stage I, Stage II, Stage III, Stage IV
- By Treatment Modality: Surgical Resection, Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy
- By Tumor Location: Colon Cancer, Rectal Cancer
- By Molecular Biomarker Status: KRAS Mutant, NRAS Mutant, BRAF Mutant, Microsatellite Instability-High (MSI-H), Microsatellite Stable (MSS)
- By Patient Demographics: Elderly Patients, Adult Patients, Pediatric Patients
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Stage I leads By Cancer Stage at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 291 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.176 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.184 →
Full report · locked preview
Everything inside the Colon and Rectal Carcinoma Market report
A complete, evidence-based study - 12 chapters and 122 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Cancer Stage 4
Treatment Modality 5
Tumor Location 2
Molecular Biomarker Status 5
Patient Demographics 3
Companies profiled
Roche
Pfizer
Merck & Co.
Bristol-Myers Squibb
Amgen
Novartis
AstraZeneca
Sanofi
Eli Lilly and Company
Johnson & Johnson
Bayer
Takeda Pharmaceutical Company
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Roche
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Pfizer
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Merck & Co.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Bristol-Myers Squibb
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Amgen
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Novartis
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →AstraZeneca
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Sanofi
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Eli Lilly and Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Johnson & Johnson
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Bayer
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Takeda Pharmaceutical Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →AbbVie
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →GlaxoSmithKline
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Seattle Genetics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$3,840M by 2033 · 9.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Stage I58.2
- Stage II18.3
- Stage III9.1
- Stage IV14.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$612.3M → $1,202M · 8.8%
Europe$426.8M → $797.8M · 8.1%
Asia Pacific$389.7M → $811.0M · 9.6%
Latin America$241.2M → $508.2M · 9.8%
Middle East and Africa$185.6M → $376.5M · 9.2%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.472026
9.492027
9.502028
9.502029
9.512030
9.542031
9.532032
9.552033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Roche17.5
- Pfizer22.6
- Merck & Co.10.4
- Bristol-Myers Squibb5.6
- Amgen6.6
- Novartis9.2
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Cancer Stage28.3%
Treatment Modality15.1%
Tumor Location22.6%
Molecular Biomarker Status23.6%
Patient Demographics10.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.5
- Europe21.6
- Asia Pacific21.9
- Latin America13.8
- Middle East and Africa10.2
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Roche | 77 | 93 | 82 | 98 | 78 | 92 | 87 |
| Pfizer | 87 | 84 | 84 | 80 | 82 | 85 | 84 |
| Merck & Co. | 83 | 84 | 73 | 69 | 69 | 66 | 74 |
| Bristol-Myers Squibb | 76 | 80 | 76 | 77 | 58 | 82 | 75 |
| Amgen | 69 | 65 | 63 | 60 | 57 | 66 | 63 |
| Novartis | 69 | 52 | 54 | 67 | 71 | 59 | 62 |
| AstraZeneca | 54 | 52 | 64 | 43 | 40 | 60 | 52 |
| Sanofi | 50 | 53 | 45 | 36 | 51 | 53 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Roche
- Pfizer
- Merck & Co.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Roche | ✓ | ◐ | ✓ | ✓ | ✓ | ◐ |
| Pfizer | ✓ | ✓ | ✓ | ◐ | ◐ | ◐ |
| Merck & Co. | ✓ | ◐ | ✓ | ◐ | ◐ | − |
| Bristol-Myers Squibb | ◐ | ✓ | ✓ | ◐ | − | ◐ |
| Amgen | ◐ | ◐ | ✓ | ◐ | ◐ | ◐ |
| Novartis | ✓ | − | ◐ | ◐ | ✓ | ◐ |
| AstraZeneca | − | ◐ | − | − | − | − |
| Sanofi | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Roche87
2Pfizer84
3Bristol-Myers Squibb75
4Merck & Co.74
5Amgen63
6Novartis62
7AstraZeneca52
8Sanofi48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
RochePfizer
Challenger2
Strong scale, closing on the leaders.
Merck & Co.Bristol-Myers Squibb
Contender2
Focused players with pockets of strength.
AmgenNovartis
Niche2
Specialists in a single segment or region.
AstraZenecaSanofi
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Cancer Stage in North America, then scale across Colon and Rectal Carcinoma Market — a $696M beachhead inside a $10.8B market.
Beachhead (SOM)$696Mobtainable near-term
Serviceable (SAM)$4.07Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Stage I
Best fit — highest urgency & budget in Cancer Stage.
Economic buyer80 fit
Stage II
Strong fit — clear ROI and a fast path to value.
End user67 fit
Stage III
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Cancer Stage in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Treatment Modality & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Tumor Location
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales40%
Partner / channel28%
Digital / self-serve22%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Cancer Stage leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Colon and Rectal Carcinoma Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified22%
Evaluation12%
Closed-won8%
$14.0KCAC
$55KLTV
4.0:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Colon and Rectal Carcinoma Market is a durable-growth opportunity — $10.3B by 2033, compounding at 9.2%.
TAM · 2025$5.09Btoday
TAM · 2033$10.3Bforecast
CAGR9.2%2027–2033
Cumulative$67.0Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$10.3BTotal addressable market
SAM$4.10BServiceable available market
SOM$784MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.2% CAGR
Demand compounds through 2033, outpacing GDP across Cancer Stage.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Cancer Stage moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$10.3BLarge & growingTAM by 2033 at 9.2% CAGR
$4.10BServiceable nowreachable with today’s model
$784MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$8.05BBear6.0% CAGR
$10.3BBase9.2% CAGR
$13.2BBull12.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Treatment Modality optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Colon and Rectal Carcinoma Market — a $3.21B market by 2033. Plan: grow share from 7.1% to 15.8%.
Market size · 2033$3.21Btotal addressable
Market CAGR8.1%2027–2033
Target share15.8%from 7.1% today
Revenue ambition$506Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.1% | 15.8% | At risk |
| Revenue | $216M | $506M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 35.5% | 45.4% | On track |
| Customer retention | 88.5% | 93.6% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Cancer Stage
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Treatment Modality capability
A defensible second engine — invest in Treatment Modality to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Cancer Stage share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Treatment Modality
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $73M capacity & capability investment
- Greenlight bolt-on M&A in Treatment Modality
- Authorise North America expansion plan
- Fund R&D program for Cancer Stage leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAt risk
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Colon and Rectal Carcinoma Market conversation — a $10.5B market you can size, segment and defend in minutes.
Market size · 2033$10.5Btotal opportunity
Growth11.3%CAGR to 2033
Addressable buyers1,515+accounts in scope
Typical ROI6.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Cancer Stage
Goal Grow share in Cancer Stage
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.8×return on cost, year one
< 4 mopayback period
$81K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
RochePfizerMerck & Co.Bristol-Myers SquibbAmgenNovartisAstraZenecaSanofi+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Colon and Rectal Carcinoma Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Colon and Rectal Carcinoma Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Colon Cancer Test Kits Market
Market size, share, segmentation and regional forecast.
$361M market · 2025 base year
View reportColon Therapy Machine Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportColonoscope Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportColonoscope Video Endoscope Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportColony Counter Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportColophony Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportColor Aerial Film Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportColor Aerial Films Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportColor Aluminum Alloy Plate Market
Market size, share, segmentation and regional forecast.
$574M market · 2025 base year
View reportColor Anodized Aluminum Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportColor Changing Silica Gel Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportColor Changing Silicone Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.